Entrada Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Entrada Therapeutics has a total shareholder equity of $242.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $469.2M and $226.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$351.97m |
| Equity | US$242.36m |
| Total liabilities | US$226.83m |
| Total assets | US$469.19m |
Recent financial health updates
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Recent updates
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Financial Position Analysis
Short Term Liabilities: TRDA's short term assets ($369.8M) exceed its short term liabilities ($158.8M).
Long Term Liabilities: TRDA's short term assets ($369.8M) exceed its long term liabilities ($68.0M).
Debt to Equity History and Analysis
Debt Level: TRDA is debt free.
Reducing Debt: TRDA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable TRDA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: TRDA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 54.8% per year.